AtriCure Net Worth

AtriCure Net Worth Breakdown

  ATRC
The net worth of AtriCure is the difference between its total assets and liabilities. AtriCure's net worth represents the value of the company's equity or ownership interest. In other words, it is the amount of money that would be left over if all of AtriCure's assets were sold and all of its debts were paid off. Net worth is sometimes referred to as shareholder's equity or book value. AtriCure's net worth can be used as a measure of its financial health and stability which can help investors to decide if AtriCure is a good investment. It is also essential in determining the company's creditworthiness and ability to secure financing before investing in AtriCure stock.

AtriCure Net Worth Analysis

AtriCure's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including AtriCure's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of AtriCure's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform AtriCure's net worth analysis. One common approach is to calculate AtriCure's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares AtriCure's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing AtriCure's net worth. This approach calculates the present value of AtriCure's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of AtriCure's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate AtriCure's net worth. This involves comparing AtriCure's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into AtriCure's net worth relative to its peers.

Enterprise Value

54.87 Million

To determine if AtriCure is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding AtriCure's net worth research are outlined below:
AtriCure generated a negative expected return over the last 90 days
The company reported the previous year's revenue of 399.25 M. Net Loss for the year was (30.44 M) with profit before overhead, payroll, taxes, and interest of 245.94 M.
Over 97.0% of the company shares are held by institutions such as insurance companies
Latest headline from investing.com: Oppenheimer upgrades AtriCure stock on improved risk-reward

AtriCure Quarterly Good Will

234.78 Million

AtriCure uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in AtriCure. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to AtriCure's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
20th of February 2024
Upcoming Quarterly Report
View
7th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
20th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

Know AtriCure's Top Institutional Investors

Have you ever been surprised when a price of an equity instrument such as AtriCure is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading AtriCure backward and forwards among themselves. AtriCure's institutional investor refers to the entity that pools money to purchase AtriCure's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares
Nuveen Asset Management, Llc2023-12-31
M
Dimensional Fund Advisors, Inc.2023-12-31
M
Credit Suisse First Boston (csfb)2023-12-31
990.4 K
Timessquare Capital Management, Llc2023-12-31
976.1 K
Fiera Capital Corporation2023-12-31
881.8 K
Hood River Capital Management Llc2023-12-31
841.1 K
Loomis, Sayles & Company Lp2023-12-31
834.1 K
Bellevue Group Ag2023-12-31
817.9 K
Gw&k Investment Management, Llc2023-12-31
805.1 K
Vanguard Group Inc2023-12-31
4.8 M
Blackrock Inc2023-12-31
4.2 M
Note, although AtriCure's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Follow AtriCure's market capitalization trends

The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.13 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate AtriCure's market, we take the total number of its shares issued and multiply it by AtriCure's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.

Market Cap

60.54 Million

Project AtriCure's profitablity

AtriCure's profitability indicators refer to fundamental financial ratios that showcase AtriCure's ability to generate income relative to its revenue or operating costs. If, let's say, AtriCure is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, AtriCure's executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of AtriCure's profitability requires more research than a typical breakdown of AtriCure's financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
Last ReportedProjected for Next Year
Return On Tangible Assets(0.1)(0.10)
Return On Capital Employed(0.06)(0.06)
Return On Assets(0.05)(0.05)
Return On Equity(0.07)(0.07)
The company has Profit Margin (PM) of (0.08) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.12) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.12.
When accessing AtriCure's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures AtriCure's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of AtriCure's profitability and make more informed investment decisions.
The data published in AtriCure's official financial statements usually reflect AtriCure's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of AtriCure. For example, before you start analyzing numbers published by AtriCure accountants, it's critical to develop an understanding of what AtriCure's liquidity, profitability, and earnings quality are in the context of the Health Care Equipment & Supplies space in which it operates.
Please note, the presentation of AtriCure's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, AtriCure's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in AtriCure's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of AtriCure. Please utilize our Beneish M Score to check the likelihood of AtriCure's management manipulating its earnings.

Evaluate AtriCure's management efficiency

AtriCure has return on total asset (ROA) of (0.0324) % which means that it has lost $0.0324 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.066) %, meaning that it created substantial loss on money invested by shareholders. AtriCure's management efficiency ratios could be used to measure how well AtriCure manages its routine affairs as well as how well it operates its assets and liabilities. As of April 30, 2024, Return On Tangible Assets is expected to decline to -0.1. In addition to that, Return On Capital Employed is expected to decline to -0.06. At present, AtriCure's Other Current Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 365.1 M, whereas Other Assets are forecasted to decline to 0.95.
Last ReportedProjected for Next Year
Book Value Per Share 10.07  10.57 
Net Current Asset Value 0.00  0.00 
Tangible Asset Value 0.00  0.00 
Tangible Book Value Per Share 3.61  3.80 
Enterprise Value Over EBITDA(100.91)(95.86)
Price Book Value Ratio 3.55  3.76 
Enterprise Value Multiple(100.91)(95.86)
Price Fair Value 3.55  3.76 
Enterprise Value73.6 M54.9 M
The analysis of AtriCure's management efficiency is an essential part of evaluating and assessing the financial and operational performance of the entity. It is also vital to analyze AtriCure's future growth prospects and the overall market conditions to determine the value and potential of its stock. The analysis involves studying a range of financial metrics such as revenue, earnings, profit margins, cash flow, debt, market share, and external factors such as economic trends, industry outlook, competition, and government regulations. The goal of AtriCure Stock analysis is to determine whether it is undervalued, fairly valued, or overvalued and to make informed investment decisions.
Enterprise Value Revenue
2.7616
Revenue
399.2 M
Quarterly Revenue Growth
0.21
Revenue Per Share
8.621
Return On Equity
(0.07)
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific AtriCure insiders, such as employees or executives, is commonly permitted as long as it does not rely on AtriCure's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases AtriCure insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

AtriCure Corporate Filings

23rd of April 2024
Other Reports
ViewVerify
F4
3rd of April 2024
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
8K
27th of February 2024
An amendment to a previously filed Form 8-K
ViewVerify
10K
16th of February 2024
Annual report required by the U.S. Securities and Exchange Commission (SEC) of a company financial performance
ViewVerify
AtriCure time-series forecasting models is one of many AtriCure's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary AtriCure's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

AtriCure Earnings per Share Projection vs Actual

Be your own money manager

Our tools can tell you how much better you can do entering a position in AtriCure without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Odds Of Bankruptcy Now

   

Odds Of Bankruptcy

Get analysis of equity chance of financial distress in the next 2 years
All  Next Launch Module

AtriCure Corporate Directors

AtriCure corporate directors refer to members of an AtriCure board of directors. The board of directors generally takes responsibility for the AtriCure's affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of AtriCure's board members must vote for the resolution. The AtriCure board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.
Regina GrovesIndependent DirectorProfile
Scott DrakeIndependent DirectorProfile
Mark CollarIndependent DirectorProfile
Mark LanningIndependent DirectorProfile

How to buy AtriCure Stock?

The net worth of AtriCure is the difference between its total assets and liabilities. AtriCure's net worth represents the value of the company's equity or ownership interest. In other words, it is the amount of money that would be left over if all of AtriCure's assets were sold and all of its debts were paid off. Net worth is sometimes referred to as shareholder's equity or book value. AtriCure's net worth can be used as a measure of its financial health and stability which can help investors to decide if AtriCure is a good investment. It is also essential in determining the company's creditworthiness and ability to secure financing before investing in AtriCure stock.

Already Invested in AtriCure?

The danger of trading AtriCure is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of AtriCure is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than AtriCure. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile AtriCure is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether AtriCure offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of AtriCure's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Atricure Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Atricure Stock:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AtriCure. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area.
For information on how to trade AtriCure Stock refer to our How to Trade AtriCure Stock guide.
You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.

Complementary Tools for AtriCure Stock analysis

When running AtriCure's price analysis, check to measure AtriCure's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AtriCure is operating at the current time. Most of AtriCure's value examination focuses on studying past and present price action to predict the probability of AtriCure's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AtriCure's price. Additionally, you may evaluate how the addition of AtriCure to your portfolios can decrease your overall portfolio volatility.
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Transaction History
View history of all your transactions and understand their impact on performance
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Is AtriCure's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of AtriCure. If investors know AtriCure will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about AtriCure listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.66)
Revenue Per Share
8.621
Quarterly Revenue Growth
0.21
Return On Assets
(0.03)
Return On Equity
(0.07)
The market value of AtriCure is measured differently than its book value, which is the value of AtriCure that is recorded on the company's balance sheet. Investors also form their own opinion of AtriCure's value that differs from its market value or its book value, called intrinsic value, which is AtriCure's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because AtriCure's market value can be influenced by many factors that don't directly affect AtriCure's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between AtriCure's value and its price as these two are different measures arrived at by different means. Investors typically determine if AtriCure is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, AtriCure's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.